DBV Technologies (DBVT) EBITDA Margin (2020 - 2026)
DBV Technologies (DBVT) posted quarterly EBITDA Margin of 7228.57% for Q2 2026, down 448857.0% year-on-year from N/an in Q2 2025, and down 35.82% on a QoQ basis from 5322.22% in Q1 2026.
DBV Technologies (DBVT) EBITDA Margin (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has reported EBITDA Margin for 7 consecutive years, with 7228.57% the latest figure, recorded in Q2 2026.
- Quarterly EBITDA Margin fell 448857.0% year-over-year to 7228.57% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3543.1% (down 44317.0% YoY) and the FY2025 annual result came in at 2609.23%, up 16670.0% from the prior year.
- EBITDA Margin fell to 7228.57% in Q2 2026 per DBVT's latest filing, from 5322.22% in the prior quarter.
- Over the last five years, EBITDA Margin for DBVT reached as high as 2915.41% in Q4 2022 and fell as low as 7228.57% in Q2 2026.
- A 5-year average of 2333.67% and a median of 1793.89% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2022 — EBITDA Margin soared 337507 bps — and 2026, when it sank 448857 bps.
- Year by year, EBITDA Margin stood at 2915.41% in 2022, then tumbled by 105 bps to 134.31% in 2023, then plunged by 3072 bps to 4260.89% in 2024, then plunged by 64 bps to 6984.65% in 2025, then retreated by 3 bps to 7228.57% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 7228.57%, 5322.22%, and 6984.65% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | DBV Technologies | 267.50 Mn | 92.60 Mn | - | -7,228.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,228.57% |
| Mar 31, 2026 | -5,322.22% |
| Dec 31, 2025 | -6,984.65% |
| Sep 30, 2025 | -1,235.65% |
| Jun 30, 2025 | -2,740.00% |
| Mar 31, 2025 | -3,325.00% |
| Dec 31, 2024 | -4,260.89% |
| Sep 30, 2024 | -2,829.10% |
| Jun 30, 2024 | -2,914.90% |
| Mar 31, 2024 | -2,029.71% |
| Dec 31, 2023 | -134.31% |
| Sep 30, 2023 | -770.24% |
| Jun 30, 2023 | -1,095.98% |
| Mar 31, 2023 | -964.68% |
| Dec 31, 2022 | 2,915.41% |
| Sep 30, 2022 | -868.85% |
| Jun 30, 2022 | -1,558.08% |
| Mar 31, 2022 | -658.72% |
| Dec 31, 2021 | -459.65% |
| Sep 30, 2021 | -1,841.87% |